Skip to content

Hepatocellular carcinoma — patient experience and advocacy

TL;DR — HCC experience is a coupled cancer-and-cirrhosis journey: fatigue, pain, appetite/weight change, ascites, encephalopathy, treatment toxicity, and uncertainty are difficult to attribute to one disease process. A qualitative-literature review identified five recurrent quality-of-life domains—physical symptoms/treatment effects, psychological impact/coping, social function/stigma, spiritual meaning/self, and pervasive uncertainty (Norman 2022, PMID 35974658). International interviews found treatment decisions predominantly clinician-led, despite patients having goals that changed by stage and treatment context (Wörns 2024, PMID 39052152). Caregivers report feeling unprepared and unable to distinguish cirrhosis from HCC symptoms, particularly near end of life (Hansen 2017, PMID 28820518). Advocacy priorities therefore extend beyond drug access to understandable decision support, surveillance navigation, transplant equity, symptom care, caregiver preparation, and stigma reduction.

Evidence and ethics boundary

This page synthesizes published qualitative studies, patient-reported outcomes, and verified public organization resources. It reports themes in aggregate, paraphrases rather than reproduces testimony, and does not record identifying details of private individuals.

The deeper source audit is in patient voice.

The dual-disease burden

Experience Possible HCC contribution Possible cirrhosis/treatment contribution Why attribution matters
Fatigue Cancer inflammation/burden Cirrhosis, anemia, TKI/IO, sleep May signal progression, toxicity, or decompensation
Appetite/weight loss Tumor and systemic inflammation Ascites, nausea, medication, sarcopenia Nutrition and frailty affect eligibility
Abdominal discomfort Tumor capsule/mass Ascites, procedures New severe pain can be urgent
Cognitive change Advanced illness Hepatic encephalopathy, medication, infection Encephalopathy needs prompt recognition
Bleeding Tumor/therapy Portal hypertension, anti-VEGF Can be life-threatening
Breathlessness Metastatic/effusion Ascites, anemia, infection Multiple pathways require assessment

Caregivers in longitudinal interviews specifically struggled to determine whether symptoms came from HCC or cirrhosis, increasing uncertainty and information needs (Hansen 2017, PMID 28820518).

Symptom and treatment burden

A 25-patient qualitative interview study developed an HCC conceptual model from patient-reported signs, symptoms, and impacts and mapped these against existing outcome instruments. Participants described fatigue, appetite/weight change, abdominal symptoms, sleep, physical limitation, and emotional/social effects that were not fully captured by a single measure (Patel 2022, PMID 34115280).

Treatment Patient-experience burden
Resection Pain, temporary dependency, uncertainty about recurrence
Ablation Procedure anxiety, repeated imaging, possibility of retreatment
TACE Post-embolization symptoms, admissions, repeated cycles
TARE/radiation Planning burden, delayed fatigue/toxicity, response uncertainty
TKI Daily adherence, hand-foot reaction, diarrhea, appetite and blood-pressure effects
IO Infusion logistics and unpredictable multisystem immune toxicity
Transplant Waiting/dropout uncertainty, caregiver logistics, lifelong immunosuppression

Treatment burden should be measured alongside response and survival, especially when regimens have similar efficacy.

Pervasive uncertainty

The qualitative review of 11 studies named pervasive uncertainty as a cross-cutting domain (Norman 2022, PMID 35974658). It appears at each transition:

  • Will surveillance find a cancer?
  • Is an indeterminate nodule malignant?
  • Is curative treatment technically possible?
  • Will downstaging succeed before wait-list dropout?
  • Is post-treatment enhancement viable tumor?
  • Is fatigue toxicity, cirrhosis, or progression?
  • Which first-line regimen is best without head-to-head data?
  • When does disease-directed treatment cease to help?

Uncertainty cannot always be removed, but its source, probability, and next decision point can be made explicit.

Decision-making and information

An international qualitative study interviewed 50 patients and 12 clinicians. Patients described decisions as mostly clinician-led; goals varied across surgery, locoregional therapy, and systemic stages (Wörns 2024, PMID 39052152).

Decision-support need Minimum content
Diagnosis Confidence, pathology/imaging basis, alternatives
Stage Tumor extent, liver function, performance status
Options Curative versus control intent; no-treatment option
Benefits Absolute response/survival where available
Harms Liver decompensation and treatment-specific toxicity
Burden Visits, procedures, oral adherence, caregiver time
Future pathways Transplant, salvage, next line, trial
Reassessment When and by what criterion the plan changes

A 2025 qualitative study specifically examined the role of preferences in multidisciplinary HCC decisions, highlighting the need to elicit what patients value rather than assume technical eligibility determines choice (Moon 2025, PMID 40453415).

Treatment preferences

Japanese patients with intermediate/advanced HCC completed a preference study comparing features of TACE, hepatic arterial infusion, and oral therapy. Preferences reflected tradeoffs among administration, efficacy, and adverse effects rather than one universally favored modality (Chiba 2019, PMID 31118587).

Preference data are context-specific. Access, insurance, travel, cultural expectations, family roles, and clinician framing can change the apparent value of an option.

Stigma and blame

HCC can inherit stigma from HBV/HCV, alcohol, obesity, and “lifestyle” narratives. The qualitative review identified social function and stigma as a core domain (Norman 2022, PMID 35974658).

Stigma can operate through:

  • assumptions about alcohol or drug use;
  • blame attached to body weight or diabetes;
  • fear of viral transmission;
  • reluctance to disclose diagnosis;
  • moral judgments about transplant deservingness;
  • delayed testing or care seeking.

Etiologic prevention and responsibility should not be translated into individual blame. Mixed etiologies and structural exposure are common.

Transplant waiting and survivorship

Transplant creates a distinctive sequence: evaluation, eligibility uncertainty, repeated bridging treatment, wait-list monitoring, possible dropout, surgery, and lifelong survivorship.

Qualitative work with liver-transplant recipients and caregivers identified early recovery challenges across physical, emotional, psychological, social, and healthcare-navigation domains (Lieber 2022, PMID 34529886). A related 20-recipient study developed a survivorship model emphasizing recurrence concerns, quality of life, competing health risks, motivations, and coping (Lieber 2021, PMID 33942480).

These studies include transplant indications beyond HCC, so their findings are supportive rather than HCC-specific.

Caregiver burden

In longitudinal qualitative work, 13 family caregivers completed 39 interviews near the patient's end of life. They reported being unprepared, uncertain, and in need of information, particularly about symptom interpretation and treatment challenges (Hansen 2017, PMID 28820518).

Caregiver work includes:

  • transport and appointment coordination;
  • medication and symptom monitoring;
  • responding to encephalopathy or bleeding;
  • financial and employment disruption;
  • transplant logistics;
  • decision support when cognition or illness worsens;
  • bereavement preparation.

Caregiver capacity is clinically relevant but should not become an inequitable hidden eligibility criterion.

End-of-life experience and palliative care

A longitudinal study followed 14 patients with terminal HCC through 45 monthly interviews. Themes included illness perceptions, the decision to begin treatment, navigating treatment over time, symptom challenges, and unmet information needs (Hansen 2015, PMID 25122134).

Palliative care is compatible with active cancer and transplant evaluation. A rapid review found high symptom burden and plausible benefit but limited intervention evidence in decompensated cirrhosis/HCC, indicating underdevelopment rather than lack of need (Mudumbi 2018, PMID 29698124).

Early supportive care can address:

  • symptoms and nutrition;
  • uncertainty and coping;
  • goals and treatment burden;
  • caregiver preparation;
  • advance care planning;
  • transitions when liver failure or cancer progresses.

Patient-reported outcomes in trials

REFLECT patient-reported outcomes compared lenvatinib and sorafenib, demonstrating that quality-of-life trajectories can differentiate regimens beyond a non-inferior survival endpoint (Vogel 2021, PMID 34087115).

Trial PRO interpretation should report:

  • completion and missingness by arm;
  • time to deterioration and definition;
  • liver-specific versus cancer-generic instruments;
  • clinically meaningful difference;
  • survivor bias;
  • whether deterioration preceded treatment discontinuation.

Advocacy ecosystem

Organization/resource Role Verified public URL (accessed 2026-08-30)
Liver Cancer UK HCC/liver-cancer information, support, awareness https://www.livercanceruk.org/
Blue Faery: The Adrienne Wilson Liver Cancer Association HCC education and advocacy https://www.bluefaery.org/
International Liver Cancer Association Professional education with patient-facing relevance https://ilca-online.org/
Macmillan Cancer Support — liver cancer Cancer information and support https://www.macmillan.org.uk/cancer-information-and-support/liver-cancer

The American Liver Foundation and American Cancer Society URLs were attempted but returned HTTP 403/406 to the retrieval method; they are recorded as access-limited in the patient-voice source file rather than treated as fully verified content sources.

Advocacy priorities

  1. Close surveillance and diagnostic follow-up gaps.
  2. Make multidisciplinary decisions legible to patients.
  3. Reduce etiologic stigma and transplant moralization.
  4. Include caregivers in symptom-safety education with consent.
  5. Measure quality of life and treatment burden in every stage.
  6. Improve geographic and socioeconomic transplant access.
  7. Include Child-Pugh B and underrepresented etiologies in research.
  8. Integrate palliative care before crisis.

Quality of life is an outcome, not a side note

A 45-study review found pain, fatigue, sleep disturbance, distress, and appetite loss across stages, including years after treatment; cirrhosis, later tumor stage, recurrence, living alone, unemployment, and several demographic factors were associated with worse HRQoL (Kang 2020, PMID 32410403). An earlier 36-study synthesis found HCC affects physical, emotional, and functional domains more than social/family domains and highlighted liver function and recurrence as major determinants (Fan 2010, PMID 20304101). These reviews use different instruments and cannot be collapsed into one summary score.

Decision domain Patient-centered evidence Practical consequence
Surveillance test Sensitivity carried 51.3% of preference importance; simulated preference was 29.0% for abbreviated MRI versus 3.4% for ultrasound alone Patients may accept cost/logistical burden for higher detection, but preferences vary (Woolen 2022, PMID 33618022)
Unresectable treatment 200 US respondents valued 10 additional months of maintained daily function at least as much as 10 months of OS Decision aids must present function and toxicity, not OS alone (Li 2023, PMID 36900262)
Advanced treatment across countries 150 European patients ranked OS first but were willing to trade survival to reduce diarrhea, hypertension, waiting, and infusion burden Preferences are not reducible to a single utility weight (Lo 2021, PMID 34313150)
Tislelizumab versus sorafenib Deterioration HR 0.68 for global health/QoL, 0.45 for physical function, and 0.47 for fatigue A non-inferior OS regimen can differ materially in lived toxicity (Finn 2024, PMID 39435268)
Locoregional therapy Systematic review favored RFA over surgery for HRQoL for up to three years and TARE over TACE in reported studies Strong selection and instrument heterogeneity limit causal ranking (Das 2019, PMID 31685362)
Palliative care Pilot randomized study enrolled 57 of 109 approached patients and retained 52/57 Integration is feasible; definitive symptom and utilization effects need a powered trial (Verma 2023, PMID 36149682)

The two-disease burden

Symptoms and uncertainty come from both cancer and chronic liver disease. A mixed-method review of 95 studies from 26 countries and 37,283 patients found reduced quality of life, information/support gaps, and stigma across liver diseases (Grønkjær 2021, PMID 34805816). Ascites, encephalopathy, pruritus, muscle loss, dietary constraints, and fear of decompensation can dominate even when tumor imaging is stable; conversely, tumor progression can be psychologically urgent before it is symptomatic.

Clinicians also experience structural difficulty. A mixed-method study of 214 US professionals identified gaps in surveillance, imaging/biopsy decisions, risk-benefit comparison, sequencing, and guideline application (Jacobs 2023, PMID 36106593). This helps explain why patient journeys involve repeated handoffs among hepatology, oncology, radiology, surgery, transplant, and palliative care. Multidisciplinary care must include a named coordinator and a closed-loop plan, not only a conference.

Financial and logistical toxicity

Economic burden evidence is geographically uneven. A Greater China review found only 27 eligible studies among 39,930 records, with heterogeneous methods, perspectives, and data sources; it documents substantial household and health-system burden but does not support a single transferable cost estimate (Zou 2022, PMID 35530735). Transport, time off work, caregiving, repeated imaging, endoscopy, infusion visits, oral-drug copayments, and transplant relocation are distinct burdens and should be measured separately.

Systemic-therapy HRQoL evidence is similarly fragmented. A 29-study review including 10,472 patients used eight instruments and found declines with both atezolizumab-bevacizumab and sorafenib relative to baseline in reported studies, while cross-trial comparison remained difficult (Jayabalan 2025, PMID 40230581). Network meta-analysis can integrate time-to-deterioration with survival, but indirect comparisons inherit trial-population and instrument differences (Celsa 2025, PMID 40810932).

Decision-quality minimum dataset

Element What should be explicit
Goal Cure, bridge, downstage, delay progression, relieve symptoms, or preserve transplant eligibility
Benefit Absolute response probability, median/time-specific survival, uncertainty, and whether evidence matches liver function
Burden Visits, procedures, admissions, oral adherence, travel, caregiver time, and out-of-pocket cost
Toxicity Common, serious, irreversible, and treatment-specific risks in absolute terms where known
Liver tradeoff Risk that treatment damages reserve or closes a later option
Alternative Including observation, supportive care, trial, or a different modality
Reassessment Date, test, response definition, and stopping/migration rule
Preference Which outcome the patient most wants to preserve and which toxicity is least acceptable

Preference-elicitation tools remain thin: a scoping review found only ten HCC publications/abstracts evaluating formal methods (Ritaccio 2024, PMID 38418997). Tools should support, not replace, dialogue; stated preferences in hypothetical scenarios may change after a bleed, decompensation, response, or transplant listing.

Controversies

  • Survival versus function. Trial primary endpoints prioritize OS/PFS, while patients may value maintained daily function equally or more (Li 2023, PMID 36900262).
  • Early palliative care. Feasibility is demonstrated, but HCC-specific powered outcome evidence remains sparse; absence of evidence should not be mistaken for lack of symptom need (Verma 2023, PMID 36149682).
  • Whose preferences. Patients, caregivers, clinicians, payers, and transplant systems can rank the same tradeoffs differently. The patient's informed preference should be documented, not inferred (Ritaccio 2024, PMID 38418997).
  • Instrument comparability. QLQ-C30/HCC18, FACT-Hep, EQ-5D, and symptom scales capture overlapping but non-identical constructs; a statistically significant score difference may not reach a patient-important threshold (Jayabalan 2025, PMID 40230581).

Open questions

  • Which decision aid measurably increases preference-concordant HCC care (Wörns 2024, PMID 39052152)?
  • How should trials separate symptoms of tumor, cirrhosis, and treatment (Patel 2022, PMID 34115280)?
  • What caregiver intervention reduces uncertainty and emergency burden (Hansen 2017, PMID 28820518)?
  • How do stigma and transplant deservingness affect access across etiologies?
  • Which PRO domains should be core outcomes for HCC trials?

References

  1. Norman EML, Weil J, Philip J. Hepatocellular carcinoma and its impact on quality of life: a review of the qualitative literature. Eur J Cancer Care (Engl). 2022;31:e13672. PMID 35974658
  2. Wörns MA, et al. Patient experience of hepatocellular carcinoma and their treatment goals: an international qualitative study and patient journey map. Adv Ther. 2024;41:3598-3614. PMID 39052152
  3. Patel N, et al. Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study. Qual Life Res. 2022;31:473-485. PMID 34115280
  4. Hansen L, et al. Patients with hepatocellular carcinoma near the end of life: a longitudinal qualitative study. Cancer Nurs. 2015;38:E19-E27. PMID 25122134
  5. Hansen L, et al. Living with hepatocellular carcinoma near the end of life: family caregivers' perspectives. Oncol Nurs Forum. 2017;44:562-570. PMID 28820518
  6. Lieber SR, et al. Early survivorship after liver transplantation: a qualitative study identifying challenges in recovery. Liver Transpl. 2022;28:422-436. PMID 34529886
  7. Lieber SR, et al. What survivorship means to liver transplant recipients. Liver Transpl. 2021;27:1454-1467. PMID 33942480
  8. Chiba T, et al. Japanese patient preferences regarding intermediate to advanced HCC treatments. Patient Prefer Adherence. 2019;13:637-647. PMID 31118587
  9. Moon AM, et al. Exploring the role of patient preferences in HCC treatment decisions: a qualitative study. MDM Policy Pract. 2025;10:23814683251340055. PMID 40453415
  10. Vogel A, et al. Lenvatinib versus sorafenib: patient-reported outcomes from REFLECT. Lancet Gastroenterol Hepatol. 2021;6:649-658. PMID 34087115
  11. Mudumbi SK, et al. Palliative care and hospice interventions in decompensated cirrhosis and HCC: a rapid review. J Palliat Med. 2018;21:1177-1184. PMID 29698124
  12. Jacobs G, et al. Clinical care in HCC: a mixed-methods assessment of oncology professionals. Cancer Med. 2023;12:3670-3683. PMID 36106593
  13. Das A, et al. HRQoL outcomes in locoregional therapies for HCC: a systematic review. J Vasc Interv Radiol. 2019;30:1924-1933.e2. PMID 31685362
  14. Zou H, et al. Economic burden and quality of life of HCC in Greater China: a systematic review. Front Public Health. 2022;10:801981. PMID 35530735
  15. Kang D, et al. HRQoL studies in HCC from 2009 to 2018: a systematic review. Korean J Radiol. 2020;21:633-646. PMID 32410403
  16. Fan SY, et al. Health-related quality of life in HCC: a systematic review. Clin Gastroenterol Hepatol. 2010;8:559-564.e1-10. PMID 20304101
  17. Grønkjær LL, et al. Quality of life and unmet needs in chronic liver disease: mixed-method review. JHEP Rep. 2021;3:100370. PMID 34805816
  18. Jayabalan D, et al. HCC and HRQoL outcomes from systemic therapies: a systematic review. Int J Hepatol. 2025;2025:1083642. PMID 40230581
  19. Li D, et al. Patient preferences for unresectable HCC treatments: a discrete-choice experiment. Cancers. 2023;15. PMID 36900262
  20. Woolen SA, et al. Patient preferences for HCC surveillance parameters. Clin Gastroenterol Hepatol. 2022;20:204-215.e6. PMID 33618022
  21. Ritaccio G, et al. Values-elicitation tools for HCC treatment decisions: a scoping review. BMC Gastroenterol. 2024;24:90. PMID 38418997
  22. Lo SH, et al. Patient preferences for advanced HCC treatment: a multicountry study. Future Oncol. 2021;17:4275-4287. PMID 34313150
  23. Verma M, et al. Palliative care within routine HCC care: a pilot randomized trial. J Palliat Med. 2023;26:334-341. PMID 36149682
  24. Celsa C, et al. Integrating quality of life and survival in advanced-HCC systemic therapy. JAMA Oncol. 2025;11:1160-1168. PMID 40810932
  25. Finn RS, et al. Tislelizumab versus sorafenib: HRQoL in RATIONALE-301. Liver Cancer. 2024;13:548-560. PMID 39435268